P61073
PR
Gene name |
CXCR4 |
Protein name |
C-X-C chemokine receptor type 4 |
Names |
|
Species |
Homo sapiens (Human) |
KEGG Pathway |
hsa:7852 |
EC number |
|
Protein Class |
|
Descriptions
The autoinhibited protein was predicted that may have potential autoinhibitory elements via cis-regPred.
Autoinhibitory domains (AIDs)
Target domain |
|
Relief mechanism |
|
Assay |
cis-regPred |
Accessory elements
No accessory elements
Autoinhibited structure
Activated structure
13 structures for P61073
| Entry ID | Method | Resolution | Chain | Position | Source |
|---|---|---|---|---|---|
| 2K03 | NMR | - | B/D | 1-38 | PDB |
| 2K04 | NMR | - | B/D | 1-38 | PDB |
| 2K05 | NMR | - | B/D | 1-38 | PDB |
| 2N55 | NMR | - | B | 1-38 | PDB |
| 3ODU | X-ray | 250 A | A/B | 2-319 | PDB |
| 3OE0 | X-ray | 290 A | A | 2-319 | PDB |
| 3OE6 | X-ray | 320 A | A | 2-325 | PDB |
| 3OE8 | X-ray | 310 A | A/B/C | 2-319 | PDB |
| 3OE9 | X-ray | 310 A | A/B | 2-319 | PDB |
| 4RWS | X-ray | 310 A | PDB | ||
| 8GP3 | EM | 480 A | U/V | 336-352 | PDB |
| 8I0Q | EM | 445 A | U/V | 336-352 | PDB |
| AF-P61073-F1 | Predicted | AlphaFoldDB |
212 variants for P61073
| Variant ID(s) | Position | Change | Description | Diseaes Association | Provenance |
|---|---|---|---|---|---|
|
CA56886593 RCV001210821 rs560844176 |
7 | Y>H | Warts, hypogammaglobulinemia, infections, and myelokathexis [ClinVar] | Yes |
ClinGen ClinVar dbSNP gnomAD |
|
rs1684870931 RCV001070522 |
45 | Y>missing | Warts, hypogammaglobulinemia, infections, and myelokathexis [ClinVar] | Yes |
ClinVar dbSNP |
|
RCV001817066 RCV002065464 rs56400844 RCV001357354 CA1890152 RCV000880790 |
53 | I>L | Warts, hypogammaglobulinemia, infections, and myelokathexis WHIM syndrome 1 [ClinVar] | Yes |
ClinGen ClinVar 1000Genomes ESP ExAC TOPMed dbSNP gnomAD |
|
CA1890143 RCV002505515 RCV001221453 RCV000997208 rs368016542 |
84 | D>H | Warts, hypogammaglobulinemia, infections, and myelokathexis WHIM syndrome 1 [ClinVar] | Yes |
ClinGen ClinVar ESP ExAC TOPMed dbSNP gnomAD |
|
RCV000809796 CA1890144 rs368016542 |
84 | D>N | Warts, hypogammaglobulinemia, infections, and myelokathexis [ClinVar] | Yes |
ClinGen ClinVar ESP ExAC TOPMed dbSNP gnomAD |
|
rs1684862940 RCV001321128 |
113 | H>P | Warts, hypogammaglobulinemia, infections, and myelokathexis [ClinVar] | Yes |
ClinVar dbSNP |
|
CA56886538 rs1001278766 RCV001267757 |
125 | L>V | Warts, hypogammaglobulinemia, infections, and myelokathexis [ClinVar] | Yes |
ClinGen ClinVar TOPMed dbSNP |
|
rs1553457905 CA348658924 RCV000637060 |
153 | E>A | Warts, hypogammaglobulinemia, infections, and myelokathexis [ClinVar] | Yes |
ClinGen ClinVar Ensembl dbSNP |
|
CA1890115 RCV000818217 rs147198552 |
160 | V>I | Variant assessed as Somatic; 0.0 impact. Warts, hypogammaglobulinemia, infections, and myelokathexis [NCI-TCGA, ClinVar] | Yes |
ClinGen ClinVar ESP ExAC NCI-TCGA TOPMed dbSNP gnomAD |
|
rs371317659 CA1890112 RCV002275159 RCV000823940 |
169 | I>T | Warts, hypogammaglobulinemia, infections, and myelokathexis [ClinVar] | Yes |
ClinGen ClinVar ESP ExAC TOPMed dbSNP gnomAD |
|
RCV000983441 rs199535487 CA1890111 |
171 | D>N | Warts, hypogammaglobulinemia, infections, and myelokathexis [ClinVar] | Yes |
ClinGen ClinVar ExAC TOPMed dbSNP gnomAD |
|
RCV002533898 CA1890101 rs769772228 RCV000821606 RCV000762281 |
194 | L>F | Warts, hypogammaglobulinemia, infections, and myelokathexis Inborn genetic diseases [ClinVar] | Yes |
ClinGen ClinVar ExAC TOPMed dbSNP gnomAD |
|
CA1890100 rs748098105 RCV001324968 |
196 | V>M | Warts, hypogammaglobulinemia, infections, and myelokathexis [ClinVar] | Yes |
ClinGen ClinVar ExAC dbSNP gnomAD |
|
rs1406988415 CA348658280 RCV001308758 |
217 | S>Y | Warts, hypogammaglobulinemia, infections, and myelokathexis [ClinVar] | Yes |
ClinGen ClinVar dbSNP gnomAD |
|
rs1684851586 RCV001337584 |
221 | I>L | Warts, hypogammaglobulinemia, infections, and myelokathexis [ClinVar] | Yes |
ClinVar dbSNP |
|
rs377287446 RCV000821595 CA1890082 |
235 | R>H | Warts, hypogammaglobulinemia, infections, and myelokathexis [ClinVar] | Yes |
ClinGen ClinVar ESP ExAC TOPMed dbSNP gnomAD |
|
RCV003147549 RCV000798772 rs762937679 CA56886474 |
243 | I>L | Warts, hypogammaglobulinemia, infections, and myelokathexis WHIM syndrome 1 [ClinVar] | Yes |
ClinGen ClinVar TOPMed dbSNP gnomAD |
|
RCV001060356 rs1684843543 |
310 | K>E | Warts, hypogammaglobulinemia, infections, and myelokathexis [ClinVar] | Yes |
ClinVar dbSNP |
|
RCV002481839 RCV001027567 rs1573613529 |
317 | L>missing | Inherited Immunodeficiency Diseases WHIM syndrome 1 [ClinVar] | Yes |
ClinVar dbSNP |
|
RCV001035858 rs1684841455 |
319 | S>missing | Warts, hypogammaglobulinemia, infections, and myelokathexis [ClinVar] | Yes |
ClinVar dbSNP |
|
RCV001339385 rs1684840786 RCV001801249 |
324 | S>missing | Warts, hypogammaglobulinemia, infections, and myelokathexis WHIM syndrome 1 [ClinVar] | Yes |
ClinVar dbSNP |
|
RCV001231506 rs1684840650 |
325 | S>G | Warts, hypogammaglobulinemia, infections, and myelokathexis [ClinVar] | Yes |
ClinVar dbSNP |
|
RCV000696270 CA348657493 rs1240625960 |
332 | G>* | Warts, hypogammaglobulinemia, infections, and myelokathexis [ClinVar] | Yes |
ClinGen ClinVar dbSNP gnomAD |
|
RCV001509163 rs104893624 COSM204665 CA123711 RCV001801237 RCV000015063 |
334 | R>* | Warts, hypogammaglobulinemia, infections, and myelokathexis large_intestine Variant assessed as Somatic; impact. WHIM syndrome 1 [ClinVar, Cosmic, NCI-TCGA] | Yes |
ClinGen cosmic curated ClinVar Ensembl NCI-TCGA dbSNP |
| VAR_081113 | 334 | R>del | WHIMS1; also found in patients with Waldenstroem macroglobulinemia; somatic mutation [UniProt] | Yes | UniProt |
|
RCV003151052 CA1890055 RCV000413464 rs147214773 RCV001057995 |
335 | G>S | Warts, hypogammaglobulinemia, infections, and myelokathexis [ClinVar] | Yes |
ClinGen ClinVar ESP ExAC TOPMed dbSNP gnomAD |
|
rs104893626 RCV000015067 RCV001568992 RCV001801240 CA123717 |
338 | S>* | Warts, hypogammaglobulinemia, infections, and myelokathexis Variant assessed as Somatic; impact. WHIM syndrome 1 [ClinVar, NCI-TCGA] | Yes |
ClinGen ClinVar Ensembl NCI-TCGA dbSNP |
| VAR_081114 | 338 | S>del | WHIMS1; common somatic mutation in patients with Waldenstroem macroglobulinemia; results in decreased CXCL12-triggered receptor internalization; enhanced AKT and MAPK signaling activation; confers resistance to ibrutinib-triggered apoptosis [UniProt] | Yes | UniProt |
|
rs730880320 RCV001801238 RCV000015065 |
339 | S>missing | Warts, hypogammaglobulinemia, infections, and myelokathexis WHIM syndrome 1 [ClinVar] | Yes |
ClinVar dbSNP |
|
rs148454403 CA1890052 RCV001061022 |
341 | S>Y | Warts, hypogammaglobulinemia, infections, and myelokathexis [ClinVar] | Yes |
ClinGen ClinVar ESP ExAC TOPMed dbSNP gnomAD |
|
RCV001801239 rs104893625 CA123714 |
343 | E>* | WHIM syndrome 1 [ClinVar] | Yes |
ClinGen ClinVar Ensembl dbSNP |
| VAR_081115 | 343 | E>del | WHIMS1 [UniProt] | Yes | UniProt |
|
rs750756138 CA1890050 RCV001217826 |
352 | S>G | Warts, hypogammaglobulinemia, infections, and myelokathexis [ClinVar] | Yes |
ClinGen ClinVar ExAC TOPMed dbSNP gnomAD |
|
CA348660418 rs1226785105 |
2 | E>G | No |
ClinGen TOPMed gnomAD |
|
|
rs770986091 CA1890168 |
7 | Y>C | No |
ClinGen ExAC gnomAD |
|
|
rs1289282733 CA348660300 |
10 | D>V | No |
ClinGen gnomAD |
|
|
rs1360006297 CA348660293 |
11 | N>S | No |
ClinGen gnomAD |
|
|
CA1890167 rs762966305 |
13 | T>A | No |
ClinGen ExAC gnomAD |
|
|
CA348660276 rs1558837039 |
14 | E>K | Variant assessed as Somatic; impact. [NCI-TCGA] | No |
ClinGen Ensembl NCI-TCGA |
|
CA348660271 rs1360656571 |
14 | E>V | No |
ClinGen gnomAD |
|
|
CA1890165 rs770327175 |
17 | G>D | Variant assessed as Somatic; 0.0 impact. [NCI-TCGA] | No |
ClinGen ExAC NCI-TCGA TOPMed gnomAD |
|
CA348660248 rs770327175 |
17 | G>V | No |
ClinGen ExAC TOPMed gnomAD |
|
|
CA348660241 rs1363377230 |
18 | S>L | No |
ClinGen gnomAD |
|
|
CA1890163 rs748493255 |
23 | S>P | No |
ClinGen ExAC gnomAD |
|
|
rs1387554691 CA348660192 |
25 | K>R | Variant assessed as Somatic; 0.0 impact. [NCI-TCGA] | No |
ClinGen NCI-TCGA gnomAD |
|
CA56886585 rs923351521 COSM94110 |
30 | R>H | lung [Cosmic] | No |
ClinGen cosmic curated TOPMed gnomAD |
|
rs1230454603 CA348660132 |
33 | N>I | No |
ClinGen TOPMed |
|
|
rs779590491 CA1890159 |
35 | N>D | No |
ClinGen ExAC gnomAD |
|
|
rs757881953 CA1890158 |
37 | N>D | No |
ClinGen ExAC gnomAD |
|
|
rs749938835 CA1890157 |
37 | N>S | No |
ClinGen ExAC gnomAD |
|
|
rs1268474896 CA348660071 |
42 | P>R | No |
ClinGen gnomAD |
|
|
rs1221387101 CA348660067 |
43 | T>A | No |
ClinGen gnomAD |
|
|
CA348660065 rs778969048 |
43 | T>N | No |
ClinGen ExAC TOPMed gnomAD |
|
|
CA1890156 rs778969048 |
43 | T>S | No |
ClinGen ExAC TOPMed gnomAD |
|
| TCGA novel | 44 | I>M | Variant assessed as Somatic; impact. [NCI-TCGA] | No | NCI-TCGA |
|
CA348660062 rs1267066087 |
44 | I>V | No |
ClinGen gnomAD |
|
|
CA1890155 rs147467366 |
46 | S>C | No |
ClinGen 1000Genomes ExAC gnomAD |
|
|
rs1359102217 CA348660035 |
48 | I>V | No |
ClinGen TOPMed |
|
|
rs1241516977 CA348660020 |
50 | L>S | No |
ClinGen TOPMed |
|
|
CA1890154 rs753680989 |
50 | L>V | No |
ClinGen ExAC gnomAD |
|
| TCGA novel | 51 | T>I | Variant assessed as Somatic; impact. [NCI-TCGA] | No | NCI-TCGA |
|
CA348660001 rs1343187033 |
53 | I>T | No |
ClinGen gnomAD |
|
|
CA56886577 rs56400844 |
53 | I>V | No |
ClinGen 1000Genomes ESP ExAC TOPMed gnomAD |
|
|
rs751756723 CA1890151 |
56 | N>D | No |
ClinGen ExAC gnomAD |
|
|
CA348659983 rs1393307051 |
56 | N>S | No |
ClinGen TOPMed gnomAD |
|
|
rs1314188521 CA348659965 |
59 | V>L | No |
ClinGen gnomAD |
|
|
rs1374176769 CA348659958 |
60 | I>N | No |
ClinGen gnomAD |
|
|
rs763059810 CA1890149 |
60 | I>V | No |
ClinGen ExAC gnomAD |
|
|
CA1890148 rs773216142 |
63 | M>T | No |
ClinGen ExAC TOPMed gnomAD |
|
|
CA348659931 rs1479506035 |
64 | G>A | No |
ClinGen gnomAD |
|
|
CA348659917 rs1428775677 |
66 | Q>R | Variant assessed as Somatic; 4.619e-05 impact. [NCI-TCGA] | No |
ClinGen NCI-TCGA gnomAD |
|
CA348659904 rs1481575745 |
68 | K>Q | No |
ClinGen gnomAD |
|
|
CA1890146 rs762377247 |
69 | L>Q | No |
ClinGen ExAC gnomAD |
|
|
CA56886571 rs1046266103 |
71 | S>N | No |
ClinGen Ensembl |
|
|
rs943396331 CA56886570 |
73 | T>M | No |
ClinGen TOPMed |
|
|
rs777131342 CA1890145 |
75 | K>E | No |
ClinGen ExAC gnomAD |
|
|
CA348659826 rs1573614635 |
79 | H>P | No |
ClinGen Ensembl |
|
|
rs1251842734 CA348659813 |
81 | S>* | No |
ClinGen gnomAD |
|
|
CA56886562 rs889949060 |
86 | L>V | No |
ClinGen Ensembl |
|
|
CA1890140 rs745368112 |
89 | I>T | No |
ClinGen ExAC |
|
|
rs1454261903 CA348659767 |
89 | I>V | No |
ClinGen TOPMed |
|
|
CA1890138 rs756830956 |
90 | T>M | No |
ClinGen ExAC gnomAD |
|
|
CA348659718 rs1397762931 |
96 | V>A | No |
ClinGen TOPMed gnomAD |
|
|
CA348659719 rs1397762931 |
96 | V>D | No |
ClinGen TOPMed gnomAD |
|
|
rs1397762931 CA348659717 |
96 | V>G | No |
ClinGen TOPMed gnomAD |
|
|
rs1333957805 CA348659716 |
97 | D>N | No |
ClinGen gnomAD |
|
|
CA1890134 rs200028262 |
99 | V>E | No |
ClinGen 1000Genomes ExAC gnomAD |
|
|
CA1890135 rs755899324 |
99 | V>M | No |
ClinGen ExAC TOPMed gnomAD |
|
|
rs766604040 CA1890133 |
100 | A>V | No |
ClinGen ExAC gnomAD |
|
|
rs1179340105 CA348659692 |
101 | N>D | No |
ClinGen gnomAD |
|
|
CA1890131 rs765237875 |
103 | Y>D | No |
ClinGen ExAC gnomAD |
|
|
CA1890130 rs765237875 |
103 | Y>H | No |
ClinGen ExAC gnomAD |
|
|
CA348659660 rs1313967515 |
105 | G>W | No |
ClinGen TOPMed |
|
|
CA348659642 rs777078340 |
107 | F>L | No |
ClinGen ExAC gnomAD |
|
|
CA1890127 rs764621696 |
114 | V>I | No |
ClinGen ExAC gnomAD |
|
|
rs1203786822 CA348659483 |
117 | T>R | No |
ClinGen gnomAD |
|
|
CA1890126 rs200796213 |
118 | V>F | No |
ClinGen 1000Genomes ExAC gnomAD |
|
|
CA1890124 rs771750319 |
132 | L>V | No |
ClinGen ExAC gnomAD |
|
|
CA348659203 rs1336721760 |
135 | Y>C | No |
ClinGen gnomAD |
|
|
CA348659157 rs1451071577 |
139 | V>I | Variant assessed as Somatic; 0.0 impact. [NCI-TCGA] | No |
ClinGen NCI-TCGA TOPMed gnomAD |
| TCGA novel | 140 | H>R | Variant assessed as Somatic; impact. [NCI-TCGA] | No | NCI-TCGA |
|
CA56886534 rs770516483 |
141 | A>P | No |
ClinGen ExAC TOPMed gnomAD |
|
|
CA1890121 rs770516483 |
141 | A>T | No |
ClinGen ExAC TOPMed gnomAD |
|
|
rs748839679 CA1890120 |
141 | A>V | No |
ClinGen ExAC gnomAD |
|
|
CA1890119 rs542113929 |
146 | R>K | No |
ClinGen 1000Genomes ExAC gnomAD |
|
|
CA1890118 rs756056714 |
150 | L>V | No |
ClinGen ExAC gnomAD |
|
|
rs1442655114 CA348658882 |
156 | V>F | No |
ClinGen gnomAD |
|
|
rs976327833 CA56886527 |
157 | Y>C | No |
ClinGen TOPMed gnomAD |
|
|
CA1890116 rs780780627 |
158 | V>A | No |
ClinGen ExAC gnomAD |
|
|
CA56886523 rs910532454 |
159 | G>C | No |
ClinGen gnomAD |
|
|
rs910532454 CA348658847 |
159 | G>S | No |
ClinGen gnomAD |
|
|
CA348658813 rs1331289711 |
161 | W>C | No |
ClinGen TOPMed |
|
| TCGA novel | 162 | I>M | Variant assessed as Somatic; impact. [NCI-TCGA] | No | NCI-TCGA |
|
rs1288565097 CA348658765 |
165 | L>F | Variant assessed as Somatic; 0.0 impact. [NCI-TCGA] | No |
ClinGen NCI-TCGA TOPMed gnomAD |
|
rs1558836549 CA348658762 |
165 | L>H | No |
ClinGen Ensembl |
|
|
rs1275891527 CA348658718 |
169 | I>V | No |
ClinGen TOPMed |
|
|
rs764678610 CA1890110 |
172 | F>L | No |
ClinGen ExAC TOPMed gnomAD |
|
|
CA348658618 rs1324744010 |
175 | A>G | No |
ClinGen gnomAD |
|
|
CA348658604 rs1274871337 |
176 | N>S | Variant assessed as Somatic; impact. [NCI-TCGA] | No |
ClinGen NCI-TCGA TOPMed |
|
CA1890107 rs767830104 |
177 | V>I | No |
ClinGen ExAC gnomAD |
|
|
CA1890108 rs767830104 |
177 | V>L | No |
ClinGen ExAC gnomAD |
|
|
rs759922650 CA1890106 |
178 | S>C | No |
ClinGen ExAC |
|
|
CA348658562 rs1354401492 |
179 | E>K | No |
ClinGen TOPMed gnomAD |
|
|
CA56886512 rs112461257 |
182 | D>E | No |
ClinGen Ensembl |
|
|
CA348658526 rs1362722627 |
182 | D>N | No |
ClinGen gnomAD |
|
|
rs774186681 CA1890105 |
184 | Y>C | No |
ClinGen ExAC TOPMed gnomAD |
|
|
CA348658501 rs774186681 |
184 | Y>S | No |
ClinGen ExAC TOPMed gnomAD |
|
|
CA1890103 rs748827835 |
185 | I>T | No |
ClinGen ExAC gnomAD |
|
|
rs1289033947 CA348658472 |
188 | R>H | No |
ClinGen gnomAD |
|
|
CA348658453 rs1473769894 |
191 | P>T | No |
ClinGen TOPMed gnomAD |
|
|
rs559623689 CA56886507 |
192 | N>K | No |
ClinGen 1000Genomes |
|
|
rs148190725 CA1890102 |
192 | N>S | No |
ClinGen 1000Genomes ESP ExAC TOPMed gnomAD |
|
|
CA56886505 rs367718547 |
193 | D>Y | No |
ClinGen ESP |
|
|
rs867008465 CA56886503 |
194 | L>T | No |
ClinGen Ensembl |
|
|
rs1447178923 CA348658425 |
195 | W>* | No |
ClinGen gnomAD |
|
| TCGA novel | 195 | W>C | Variant assessed as Somatic; impact. [NCI-TCGA] | No | NCI-TCGA |
|
rs748098105 CA348658419 |
196 | V>L | No |
ClinGen ExAC gnomAD |
|
|
rs1293027504 CA348658411 |
197 | V>A | No |
ClinGen gnomAD |
|
|
CA1890098 rs546013875 |
197 | V>I | No |
ClinGen 1000Genomes ExAC gnomAD |
|
|
rs1230501553 CA348658409 |
198 | V>M | No |
ClinGen gnomAD |
|
|
CA348658360 rs746770414 |
204 | I>N | No |
ClinGen ExAC gnomAD |
|
|
rs746770414 CA1890097 |
204 | I>T | No |
ClinGen ExAC gnomAD |
|
|
rs779132116 CA1890096 |
205 | M>K | No |
ClinGen ExAC gnomAD |
|
|
CA348658349 rs1228271428 |
206 | V>I | No |
ClinGen gnomAD |
|
|
CA348658335 rs1347254037 |
208 | L>F | No |
ClinGen gnomAD |
|
|
CA348658303 rs1383467244 |
213 | I>T | No |
ClinGen Ensembl |
|
|
rs753921469 CA1890094 |
214 | V>I | No |
ClinGen ExAC gnomAD |
|
|
rs756207760 CA56886492 |
218 | C>S | No |
ClinGen ExAC TOPMed gnomAD |
|
|
rs756207760 CA1890092 |
218 | C>Y | No |
ClinGen ExAC TOPMed gnomAD |
|
|
rs943487372 CA56886490 |
220 | C>R | No |
ClinGen TOPMed |
|
|
CA1890091 rs374458307 |
222 | I>V | No |
ClinGen ESP ExAC gnomAD |
|
|
CA1890089 rs201696064 |
225 | K>Q | No |
ClinGen 1000Genomes ExAC |
|
|
rs1196816010 CA348658211 |
228 | H>N | No |
ClinGen TOPMed gnomAD |
|
|
rs762625278 CA1890086 |
228 | H>Q | No |
ClinGen ExAC gnomAD |
|
|
rs772992625 CA1890085 |
229 | S>T | No |
ClinGen ExAC TOPMed gnomAD |
|
|
rs1419294193 CA348658178 |
233 | Q>K | No |
ClinGen gnomAD |
|
|
COSM204666 rs1272938495 CA348658160 |
235 | R>C | Variant assessed as Somatic; 0.0 impact. large_intestine [NCI-TCGA, Cosmic] | No |
ClinGen cosmic curated NCI-TCGA TOPMed gnomAD |
|
CA348658149 rs1281519417 |
237 | A>T | No |
ClinGen gnomAD |
|
|
CA348658141 rs1256938467 |
238 | L>F | Variant assessed as Somatic; impact. [NCI-TCGA] | No |
ClinGen NCI-TCGA gnomAD |
|
rs1275180583 CA348658093 |
245 | I>M | No |
ClinGen gnomAD |
|
|
rs779760942 CA1890079 |
249 | F>L | No |
ClinGen ExAC TOPMed gnomAD |
|
|
rs771851938 CA1890078 |
250 | A>T | Variant assessed as Somatic; 0.0 impact. [NCI-TCGA] | No |
ClinGen ExAC NCI-TCGA TOPMed gnomAD |
|
CA348658061 rs1488294654 |
251 | C>S | No |
ClinGen TOPMed |
|
|
rs1558836260 CA348658024 |
256 | Y>H | No |
ClinGen Ensembl |
|
|
CA1890077 rs749571357 |
257 | I>F | No |
ClinGen ExAC gnomAD |
|
|
CA348658017 rs749571357 |
257 | I>L | No |
ClinGen ExAC gnomAD |
|
|
CA348658015 rs1194919682 |
257 | I>T | No |
ClinGen TOPMed |
|
|
CA348657977 RCV000788593 rs1173681265 |
262 | D>E | No |
ClinGen ClinVar dbSNP gnomAD |
|
|
rs1275022868 CA348657983 |
262 | D>N | No |
ClinGen gnomAD |
|
|
rs1425457196 CA348657961 |
265 | I>V | Variant assessed as Somatic; 0.0 impact. [NCI-TCGA] | No |
ClinGen NCI-TCGA TOPMed gnomAD |
|
CA56886460 rs928470394 |
266 | L>F | No |
ClinGen TOPMed gnomAD |
|
| TCGA novel | 269 | I>L | Variant assessed as Somatic; impact. [NCI-TCGA] | No | NCI-TCGA |
|
rs1179799352 CA348657932 |
269 | I>T | No |
ClinGen gnomAD |
|
|
rs1459517553 CA348657927 |
270 | I>F | No |
ClinGen gnomAD |
|
|
rs755484217 CA1890072 |
270 | I>M | No |
ClinGen ExAC gnomAD |
|
|
rs1203148711 CA348657919 |
271 | K>R | No |
ClinGen gnomAD |
|
|
rs1573613685 CA348657887 |
275 | E>D | No |
ClinGen Ensembl |
|
|
CA1890071 rs751975722 |
276 | F>I | No |
ClinGen ExAC TOPMed gnomAD |
|
| TCGA novel | 278 | N>S | Variant assessed as Somatic; impact. [NCI-TCGA] | No | NCI-TCGA |
|
CA1890067 rs750087956 |
288 | E>K | No |
ClinGen ExAC gnomAD |
|
| TCGA novel | 289 | A>D | Variant assessed as Somatic; impact. [NCI-TCGA] | No | NCI-TCGA |
|
rs1021350572 CA56886448 |
289 | A>G | Variant assessed as Somatic; impact. [NCI-TCGA] | No |
ClinGen NCI-TCGA TOPMed |
|
rs1034031817 CA56886450 |
289 | A>T | No |
ClinGen gnomAD |
|
|
CA1890066 rs566813397 |
292 | F>I | No |
ClinGen 1000Genomes ExAC gnomAD |
|
| TCGA novel | 294 | H>N | Variant assessed as Somatic; impact. [NCI-TCGA] | No | NCI-TCGA |
|
rs1379060376 CA348657720 |
299 | P>L | No |
ClinGen gnomAD |
|
|
CA348657725 rs1558836146 |
299 | P>S | No |
ClinGen Ensembl |
|
|
CA348657642 rs1573613573 |
311 | T>P | No |
ClinGen Ensembl |
|
|
CA56886443 rs200994803 |
313 | A>T | No |
ClinGen TOPMed |
|
|
rs372900959 CA1890063 |
314 | Q>E | No |
ClinGen ExAC gnomAD |
|
| TCGA novel | 315 | H>Q | Variant assessed as Somatic; impact. [NCI-TCGA] | No | NCI-TCGA |
|
rs145335491 CA1890061 |
316 | A>S | No |
ClinGen ESP ExAC TOPMed gnomAD |
|
|
rs145335491 CA1890060 COSM1249498 |
316 | A>T | oesophagus [Cosmic] | No |
ClinGen cosmic curated ESP ExAC TOPMed gnomAD |
|
RCV001269935 rs1684842255 |
318 | T>missing | No |
ClinVar dbSNP |
|
|
CA348657600 rs1573613538 |
318 | T>P | No |
ClinGen Ensembl |
|
| TCGA novel | 320 | V>C | Variant assessed as Somatic; impact. [NCI-TCGA] | No | NCI-TCGA |
|
rs1443118787 CA348657587 |
320 | V>L | No |
ClinGen TOPMed |
|
|
CA1890059 rs745632311 |
322 | R>G | No |
ClinGen ExAC gnomAD |
|
| TCGA novel | 325 | S>V | Variant assessed as Somatic; impact. [NCI-TCGA] | No | NCI-TCGA |
|
CA1890057 rs770009132 |
329 | L>F | No |
ClinGen ExAC gnomAD |
|
|
rs1460342112 CA348657522 |
329 | L>R | No |
ClinGen gnomAD |
|
|
CA348657496 rs1240625960 |
332 | G>R | No |
ClinGen gnomAD |
|
| VAR_081112 | 333 | K>del | found in patients with Waldenstroem macroglobulinemia; somatic mutation [UniProt] | No | UniProt |
|
rs748189454 CA1890056 |
334 | R>P | No |
ClinGen ExAC TOPMed gnomAD |
|
| TCGA novel | 334 | R>P | Variant assessed as Somatic; impact. [NCI-TCGA] | No | NCI-TCGA |
|
CA348657465 rs748189454 |
334 | R>Q | No |
ClinGen ExAC TOPMed gnomAD |
|
|
CA1890053 rs752167988 |
337 | H>R | No |
ClinGen ExAC gnomAD |
|
|
CA348657317 rs1558835985 |
345 | E>G | No |
ClinGen Ensembl |
|
|
CA348657280 rs1573613407 |
348 | S>G | No |
ClinGen Ensembl |
|
|
rs1299134173 CA348657229 |
350 | H>Q | No |
ClinGen gnomAD |
|
|
rs1344271734 CA348657241 |
350 | H>Y | Variant assessed as Somatic; 0.0 impact. [NCI-TCGA] | No |
ClinGen NCI-TCGA TOPMed gnomAD |
| TCGA novel | 352 | S>R | Variant assessed as Somatic; impact. [NCI-TCGA] | No | NCI-TCGA |
2 associated diseases with P61073
[MIM: 193670]: WHIM syndrome 1 (WHIMS1)
An autosomal dominant immunologic disease characterized by neutropenia, hypogammaglobulinemia and extensive human papillomavirus (HPV) infection. Despite the peripheral neutropenia, bone marrow aspirates from affected individuals contain abundant mature myeloid cells, a condition termed myelokathexis. {ECO:0000269|PubMed:12692554, ECO:0000269|PubMed:15536153}. Note=The disease is caused by variants affecting the gene represented in this entry.
Without disease ID
- An autosomal dominant immunologic disease characterized by neutropenia, hypogammaglobulinemia and extensive human papillomavirus (HPV) infection. Despite the peripheral neutropenia, bone marrow aspirates from affected individuals contain abundant mature myeloid cells, a condition termed myelokathexis. {ECO:0000269|PubMed:12692554, ECO:0000269|PubMed:15536153}. Note=The disease is caused by variants affecting the gene represented in this entry.
Functions
16 GO annotations of cellular component
| Name | Definition |
|---|---|
| anchoring junction | A cell junction that mechanically attaches a cell (and its cytoskeleton) to neighboring cells or to the extracellular matrix. |
| cell leading edge | The area of a motile cell closest to the direction of movement. |
| cell surface | The external part of the cell wall and/or plasma membrane. |
| cytoplasm | The contents of a cell excluding the plasma membrane and nucleus, but including other subcellular structures. |
| cytoplasmic vesicle | A vesicle found in the cytoplasm of a cell. |
| cytosol | The part of the cytoplasm that does not contain organelles but which does contain other particulate matter, such as protein complexes. |
| early endosome | A membrane-bounded organelle that receives incoming material from primary endocytic vesicles that have been generated by clathrin-dependent and clathrin-independent endocytosis; vesicles fuse with the early endosome to deliver cargo for sorting into recycling or degradation pathways. |
| external side of plasma membrane | The leaflet of the plasma membrane that faces away from the cytoplasm and any proteins embedded or anchored in it or attached to its surface. |
| extracellular exosome | A vesicle that is released into the extracellular region by fusion of the limiting endosomal membrane of a multivesicular body with the plasma membrane. Extracellular exosomes, also simply called exosomes, have a diameter of about 40-100 nm. |
| extracellular matrix | A structure lying external to one or more cells, which provides structural support, biochemical or biomechanical cues for cells or tissues. |
| integral component of membrane | The component of a membrane consisting of the gene products and protein complexes having at least some part of their peptide sequence embedded in the hydrophobic region of the membrane. |
| late endosome | A prelysosomal endocytic organelle differentiated from early endosomes by lower lumenal pH and different protein composition. Late endosomes are more spherical than early endosomes and are mostly juxtanuclear, being concentrated near the microtubule organizing center. |
| lysosome | A small lytic vacuole that has cell cycle-independent morphology found in most animal cells and that contains a variety of hydrolases, most of which have their maximal activities in the pH range 5-6. The contained enzymes display latency if properly isolated. About 40 different lysosomal hydrolases are known and lysosomes have a great variety of morphologies and functions. |
| nucleus | A membrane-bounded organelle of eukaryotic cells in which chromosomes are housed and replicated. In most cells, the nucleus contains all of the cell's chromosomes except the organellar chromosomes, and is the site of RNA synthesis and processing. In some species, or in specialized cell types, RNA metabolism or DNA replication may be absent. |
| plasma membrane | The membrane surrounding a cell that separates the cell from its external environment. It consists of a phospholipid bilayer and associated proteins. |
| protein-containing complex | A stable assembly of two or more macromolecules, i.e. proteins, nucleic acids, carbohydrates or lipids, in which at least one component is a protein and the constituent parts function together. |
13 GO annotations of molecular function
| Name | Definition |
|---|---|
| actin binding | Binding to monomeric or multimeric forms of actin, including actin filaments. |
| C-C chemokine binding | Binding to a C-C chemokine; C-C chemokines do not have an amino acid between the first two cysteines of the characteristic four-cysteine motif. |
| C-C chemokine receptor activity | Combining with a C-C chemokine and transmitting the signal from one side of the membrane to the other to initiate a change in cell activity. C-C chemokines do not have an amino acid between the first two cysteines of the characteristic four-cysteine motif. |
| C-X-C chemokine receptor activity | Combining with a C-X-C chemokine and transmitting the signal from one side of the membrane to the other to initiate a change in cell activity. A C-X-C chemokine has a single amino acid between the first two cysteines of the characteristic four cysteine motif. |
| C-X-C motif chemokine 12 receptor activity | Combining with the C-X-C motif chemokine 12 (CXCL12) and transmitting the signal from one side of the membrane to the other to initiate a change in cell activity. |
| coreceptor activity | Combining with an extracellular or intracellular messenger, and in cooperation with a nearby primary receptor, initiating a change in cell activity. |
| G protein-coupled receptor activity | Combining with an extracellular signal and transmitting the signal across the membrane by activating an associated G-protein; promotes the exchange of GDP for GTP on the alpha subunit of a heterotrimeric G-protein complex. |
| molecular adaptor activity | The binding activity of a molecule that brings together two or more molecules through a selective, non-covalent, often stoichiometric interaction, permitting those molecules to function in a coordinated way. |
| myosin light chain binding | Binding to a light chain of a myosin complex. |
| small molecule binding | Binding to a small molecule, any low molecular weight, monomeric, non-encoded molecule. |
| ubiquitin binding | Binding to ubiquitin, a protein that when covalently bound to other cellular proteins marks them for proteolytic degradation. |
| ubiquitin protein ligase binding | Binding to a ubiquitin protein ligase enzyme, any of the E3 proteins. |
| virus receptor activity | Combining with a virus component and mediating entry of the virus into the cell. |
42 GO annotations of biological process
| Name | Definition |
|---|---|
| apoptotic process | A programmed cell death process which begins when a cell receives an internal (e.g. DNA damage) or external signal (e.g. an extracellular death ligand), and proceeds through a series of biochemical events (signaling pathway phase) which trigger an execution phase. The execution phase is the last step of an apoptotic process, and is typically characterized by rounding-up of the cell, retraction of pseudopodes, reduction of cellular volume (pyknosis), chromatin condensation, nuclear fragmentation (karyorrhexis), plasma membrane blebbing and fragmentation of the cell into apoptotic bodies. When the execution phase is completed, the cell has died. |
| brain development | The process whose specific outcome is the progression of the brain over time, from its formation to the mature structure. Brain development begins with patterning events in the neural tube and ends with the mature structure that is the center of thought and emotion. The brain is responsible for the coordination and control of bodily activities and the interpretation of information from the senses (sight, hearing, smell, etc.). |
| calcium-mediated signaling | Any intracellular signal transduction in which the signal is passed on within the cell via calcium ions. |
| cardiac muscle contraction | Muscle contraction of cardiac muscle tissue. |
| cell chemotaxis | The directed movement of a motile cell guided by a specific chemical concentration gradient. Movement may be towards a higher concentration (positive chemotaxis) or towards a lower concentration (negative chemotaxis). |
| cellular response to cytokine stimulus | Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a cytokine stimulus. |
| cellular response to organonitrogen compound | Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of an organonitrogen stimulus. An organonitrogen compound is formally a compound containing at least one carbon-nitrogen bond. |
| cellular response to xenobiotic stimulus | Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a stimulus from a xenobiotic, a compound foreign to the organism exposed to it. It may be synthesized by another organism (like ampicilin) or it can be a synthetic chemical. |
| CXCL12-activated CXCR4 signaling pathway | The series of molecular signals initiated by the binding of the C-X-C chemokine CXCL12 to a C-X-C chemokine type 4 receptor (CXCR4) on the surface of a target cell, and ending with the regulation of a downstream cellular process, e.g. transcription. |
| dendritic cell chemotaxis | The movement of a dendritic cell in response to an external stimulus. |
| detection of mechanical stimulus involved in sensory perception of pain | The series of events involved in the perception of pain in which a mechanical stimulus is received and converted into a molecular signal. |
| detection of temperature stimulus involved in sensory perception of pain | The series of events involved in the perception of pain in which a temperature stimulus is received and converted into a molecular signal. |
| endothelial cell differentiation | The process in which a mesodermal, bone marrow or neural crest cell acquires specialized features of an endothelial cell, a thin flattened cell. A layer of such cells lines the inside surfaces of body cavities, blood vessels, and lymph vessels, making up the endothelium. |
| endothelial tube morphogenesis | The process in which the anatomical structures of a tube are generated and organized from an endothelium. Endothelium refers to the layer of cells lining blood vessels, lymphatics, the heart, and serous cavities, and is derived from bone marrow or mesoderm. Corneal endothelium is a special case, derived from neural crest cells. |
| epithelial cell development | The process whose specific outcome is the progression of an epithelial cell over time, from its formation to the mature structure. An epithelial cell is a cell usually found in a two-dimensional sheet with a free surface. |
| G protein-coupled receptor signaling pathway | The series of molecular signals initiated by a ligand binding to its receptor, in which the activated receptor promotes the exchange of GDP for GTP on the alpha-subunit of an associated heterotrimeric G-protein complex. The GTP-bound activated alpha-G-protein then dissociates from the beta- and gamma-subunits to further transmit the signal within the cell. The pathway begins with receptor-ligand interaction, and ends with regulation of a downstream cellular process. The pathway can start from the plasma membrane, Golgi or nuclear membrane. |
| immune response | Any immune system process that functions in the calibrated response of an organism to a potential internal or invasive threat. |
| inflammatory response | The immediate defensive reaction (by vertebrate tissue) to infection or injury caused by chemical or physical agents. The process is characterized by local vasodilation, extravasation of plasma into intercellular spaces and accumulation of white blood cells and macrophages. |
| myelin maintenance | The process of preserving the structure and function of mature myelin. This includes maintaining the compact structure of myelin necessary for its electrical insulating characteristics as well as the structure of non-compact regions such as Schmidt-Lantermann clefts and paranodal loops. This does not include processes responsible for maintaining the nodes of Ranvier, which are not part of the myelin sheath. |
| neurogenesis | Generation of cells within the nervous system. |
| neuron migration | The characteristic movement of an immature neuron from germinal zones to specific positions where they will reside as they mature. |
| neuron recognition | The process in which a neuronal cell in a multicellular organism interprets its surroundings. |
| positive regulation of chemotaxis | Any process that activates or increases the frequency, rate or extent of the directed movement of a motile cell or organism in response to a specific chemical concentration gradient. |
| positive regulation of cold-induced thermogenesis | Any process that activates or increases the frequency, rate or extent of cold-induced thermogenesis. |
| positive regulation of cytosolic calcium ion concentration | Any process that increases the concentration of calcium ions in the cytosol. |
| positive regulation of dendrite extension | Any process that activates or increases the frequency, rate or extent of dendrite extension. |
| positive regulation of macrophage migration inhibitory factor signaling pathway | Any process that activates or increases the frequency, rate or extent of macrophage migration inhibitory factor signaling pathway. |
| positive regulation of mesenchymal stem cell migration | Any process that activates or increases the frequency, rate or extent of mesenchymal stem cell migration. |
| positive regulation of oligodendrocyte differentiation | Any process that activates or increases the frequency, rate or extent of oligodendrocyte differentiation. |
| positive regulation of vascular wound healing | Any process that increases the rate, frequency, or extent of blood vessel formation when new vessels emerge from the proliferation of pre-existing blood vessels and contribute to the series of events that restore integrity to damaged vasculature. |
| regulation of calcium ion transport | Any process that modulates the frequency, rate or extent of the directed movement of calcium ions into, out of or within a cell, or between cells, by means of some agent such as a transporter or pore. |
| regulation of cell adhesion | Any process that modulates the frequency, rate or extent of attachment of a cell to another cell or to the extracellular matrix. |
| regulation of chemotaxis | Any process that modulates the frequency, rate or extent of the directed movement of a motile cell or organism in response to a specific chemical concentration gradient. |
| regulation of programmed cell death | Any process that modulates the frequency, rate or extent of programmed cell death, cell death resulting from activation of endogenous cellular processes. |
| regulation of viral process | Any process that modulates the rate or extent of the viral life cycle, the set of processes by which a virus reproduces and spreads among hosts. |
| response to activity | Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of an activity stimulus. |
| response to hypoxia | Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a stimulus indicating lowered oxygen tension. Hypoxia, defined as a decline in O2 levels below normoxic levels of 20.8 - 20.95%, results in metabolic adaptation at both the cellular and organismal level. |
| response to morphine | Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a morphine stimulus. Morphine is an opioid alkaloid, isolated from opium, with a complex ring structure. |
| response to tacrolimus | Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a tacrolimus stimulus. |
| response to ultrasound | Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of an ultrasonic stimulus. |
| response to virus | Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a stimulus from a virus. |
| telencephalon cell migration | The orderly movement of a cell from one site to another at least one of which is located in the telencephalon. |
120 homologous proteins in AiPD
| UniProt AC | Gene Name | Protein Name | Species | Evidence Code |
|---|---|---|---|---|
| Q2YDN1 | GPR161 | G protein-coupled receptor 161 | Bos taurus (Bovine) | PR |
| Q0GBZ5 | HCRTR1 | Orexin/Hypocretin receptor type 1 | Bos taurus (Bovine) | PR |
| Q17QD8 | GPR37L1 | G-protein coupled receptor 37-like 1 | Bos taurus (Bovine) | PR |
| Q8SPN1 | PROKR2 | Prokineticin receptor 2 | Bos taurus (Bovine) | PR |
| P46626 | ADRB3 | Beta-3 adrenergic receptor | Bos taurus (Bovine) | PR |
| O46639 | TRHR | Thyrotropin-releasing hormone receptor | Bos taurus (Bovine) | PR |
| Q8SPN2 | PROKR1 | Prokineticin receptor 1 | Bos taurus (Bovine) | PR |
| B9VR26 | CMLKR1 | Chemerin-like receptor 1 | Bos taurus (Bovine) | PR |
| P18130 | ADRA1A | Alpha-1A adrenergic receptor | Bos taurus (Bovine) | PR |
| B4XF06 | GPR39 | G-protein coupled receptor 39 | Bos taurus (Bovine) | PR |
| O18913 | OPN1LW | Long-wave-sensitive opsin 1 | Felis catus (Cat) (Felis silvestris catus) | PR |
| P28683 | PRA1 | Green-sensitive opsin | Gallus gallus (Chicken) | PR |
| Q9N298 | HTR1A | 5-hydroxytryptamine receptor 1A | Pan troglodytes (Chimpanzee) | PR |
| P08099 | Rh2 | Opsin Rh2 | Drosophila melanogaster (Fruit fly) | PR |
| P06002 | ninaE | Opsin Rh1 | Drosophila melanogaster (Fruit fly) | PR |
| Q4LBB9 | Octbeta2R | Octopamine receptor beta-2R | Drosophila melanogaster (Fruit fly) | PR |
| Q8NFJ6 | PROKR2 | Prokineticin receptor 2 | Homo sapiens (Human) | PR |
| Q13585 | GPR50 | Melatonin-related receptor | Homo sapiens (Human) | PR |
| Q9BZJ6 | GPR63 | Probable G-protein coupled receptor 63 | Homo sapiens (Human) | PR |
| Q9H3N8 | HRH4 | Histamine H4 receptor | Homo sapiens (Human) | PR |
| P28336 | NMBR | Neuromedin-B receptor | Homo sapiens (Human) | PR |
| Q9Y5Y3 | GPR45 | Probable G-protein coupled receptor 45 | Homo sapiens (Human) | PR |
| P08913 | ADRA2A | Alpha-2A adrenergic receptor | Homo sapiens (Human) | PR |
| Q8TCW9 | PROKR1 | Prokineticin receptor 1 | Homo sapiens (Human) | PR |
| Q99788 | CMKLR1 | Chemerin-like receptor 1 | Homo sapiens (Human) | PR |
| P08908 | HTR1A | 5-hydroxytryptamine receptor 1A | Homo sapiens (Human) | PR |
| P30559 | OXTR | Oxytocin receptor | Homo sapiens (Human) | PR |
| P32239 | CCKBR | Gastrin/cholecystokinin type B receptor | Homo sapiens (Human) | PR |
| O60883 | GPR37L1 | G-protein coupled receptor 37-like 1 | Homo sapiens (Human) | PR |
| Q8TDU9 | RXFP4 | Relaxin-3 receptor 2 | Homo sapiens (Human) | PR |
| P04000 | OPN1LW | Long-wave-sensitive opsin 1 | Homo sapiens (Human) | PR |
| Q6U736 | OPN5 | Opsin-5 | Homo sapiens (Human) | PR |
| P34972 | CNR2 | Cannabinoid receptor 2 | Homo sapiens (Human) | PR |
| P24530 | EDNRB | Endothelin receptor type B | Homo sapiens (Human) | PR |
| P35348 | ADRA1A | Alpha-1A adrenergic receptor | Homo sapiens (Human) | PR |
| Q6W5P4 | NPSR1 | Neuropeptide S receptor | Homo sapiens (Human) | PR |
| O43613 | HCRTR1 | Orexin/Hypocretin receptor type 1 | Homo sapiens (Human) | PR |
| Q9BXC0 | HCAR1 | Hydroxycarboxylic acid receptor 1 | Homo sapiens (Human) | PR |
| P30556 | AGTR1 | Type-1 angiotensin II receptor | Homo sapiens (Human) | PR |
| Q15761 | NPY5R | Neuropeptide Y receptor type 5 | Homo sapiens (Human) | PR |
| Q8N6U8 | GPR161 | G-protein coupled receptor 161 | Homo sapiens (Human) | PR |
| Q6DWJ6 | GPR139 | Probable G-protein coupled receptor 139 | Homo sapiens (Human) | PR |
| P21462 | FPR1 | fMet-Leu-Phe receptor | Homo sapiens (Human) | PR |
| P35414 | APLNR | Apelin receptor | Homo sapiens (Human) | PR |
| P46091 | CMKLR2 | Chemerin-like receptor 2 | Homo sapiens (Human) | PR |
| P32745 | SSTR3 | Somatostatin receptor type 3 | Homo sapiens (Human) | PR |
| P41439 | FOLR3 | Folate receptor gamma | Homo sapiens (Human) | PR |
| P41597 | CCR2 | C-C chemokine receptor type 2 | Homo sapiens (Human) | PR |
| P51681 | CCR5 | C-C chemokine receptor type 5 | Homo sapiens (Human) | PR |
| P32248 | CCR7 | C-C chemokine receptor type 7 | Homo sapiens (Human) | PR |
| P19973 | Lsp1 | Lymphocyte-specific protein 1 | Mus musculus (Mouse) | PR |
| O54799 | Nmbr | Neuromedin-B receptor | Mus musculus (Mouse) | PR |
| Q64264 | Htr1a | 5-hydroxytryptamine receptor 1A | Mus musculus (Mouse) | PR |
| P51675 | Ccr1 | C-C chemokine receptor type 1 | Mus musculus (Mouse) | PR |
| Q5U431 | Gpr39 | G-protein coupled receptor 39 | Mus musculus (Mouse) | PR |
| Q99JG2 | Gpr37l1 | G-protein coupled receptor 37-like 1 | Mus musculus (Mouse) | PR |
| P97295 | Npy2r | Neuropeptide Y receptor type 2 | Mus musculus (Mouse) | PR |
| O08786 | Cckar | Cholecystokinin receptor type A | Mus musculus (Mouse) | PR |
| P56481 | Cckbr | Gastrin/cholecystokinin type B receptor | Mus musculus (Mouse) | PR |
| P30731 | Gpr83 | G-protein coupled receptor 83 | Mus musculus (Mouse) | PR |
| P97468 | Cmklr1 | Chemerin-like receptor 1 | Mus musculus (Mouse) | PR |
| P21761 | Trhr | Thyrotropin-releasing hormone receptor | Mus musculus (Mouse) | PR |
| Q5QD16 | Taar3 | Trace amine-associated receptor 3 | Mus musculus (Mouse) | PR |
| P97292 | Hrh2 | Histamine H2 receptor | Mus musculus (Mouse) | PR |
| Q9EQQ3 | Gpr63 | Probable G-protein coupled receptor 63 | Mus musculus (Mouse) | PR |
| Q924H0 | Npffr2 | Neuropeptide FF receptor 2 | Mus musculus (Mouse) | PR |
| P34971 | Adrb1 | Beta-1 adrenergic receptor | Mus musculus (Mouse) | PR |
| Q91ZY2 | Hrh4 | Histamine H4 receptor | Mus musculus (Mouse) | PR |
| O88416 | Gpr33 | Probable G-protein coupled receptor 33 | Mus musculus (Mouse) | PR |
| Q8K087 | Cmklr2 | Chemerin-like receptor 2 | Mus musculus (Mouse) | PR |
| Q9WV08 | Aplnr | Apelin receptor | Mus musculus (Mouse) | PR |
| P97718 | Adra1a | Alpha-1A adrenergic receptor | Mus musculus (Mouse) | PR |
| Q8BZP8 | Npsr1 | Neuropeptide S receptor | Mus musculus (Mouse) | PR |
| Q8K458 | Prokr2 | Prokineticin receptor 2 | Mus musculus (Mouse) | PR |
| P58308 | Hcrtr2 | Orexin receptor type 2 | Mus musculus (Mouse) | PR |
| Q7TQP3 | Gpr119 | Glucose-dependent insulinotropic receptor | Mus musculus (Mouse) | PR |
| Q8BGE9 | Rxfp3 | Relaxin-3 receptor 1 | Mus musculus (Mouse) | PR |
| Q6VZZ7 | Opn5 | Opsin-5 | Mus musculus (Mouse) | PR |
| Q8CIM5 | Gpr84 | G-protein coupled receptor 84 | Mus musculus (Mouse) | PR |
| P25962 | Adrb3 | Beta-3 adrenergic receptor | Mus musculus (Mouse) | PR |
| Q80UC8 | Gpr139 | Probable G-protein coupled receptor 139 | Mus musculus (Mouse) | PR |
| P0C5I1 | Gpr25 | Probable G-protein coupled receptor 25 | Mus musculus (Mouse) | PR |
| P47936 | Cnr2 | Cannabinoid receptor 2 | Mus musculus (Mouse) | PR |
| Q5QD13 | Taar6 | Trace amine-associated receptor 6 | Mus musculus (Mouse) | PR |
| P35846 | Folr1 | Folate receptor alpha | Mus musculus (Mouse) | PR |
| P58307 | Hcrtr1 | Orexin/Hypocretin receptor type 1 | Mus musculus (Mouse) | PR |
| Q8C131 | Hcar1 | Hydroxycarboxylic acid receptor 1 | Mus musculus (Mouse) | PR |
| Q9EQQ4 | Gpr45 | Probable G-protein coupled receptor 45 | Mus musculus (Mouse) | PR |
| B2RPY5 | Gpr161 | G-protein coupled receptor 161 | Mus musculus (Mouse) | PR |
| P70658 | Cxcr4 | C-X-C chemokine receptor type 4 | Mus musculus (Mouse) | PR |
| Q764M9 | CXCR4 | C-X-C chemokine receptor type 4 | Sus scrofa (Pig) | PR |
| Q9EQD2 | Npffr2 | Neuropeptide FF receptor 2 | Rattus norvegicus (Rat) | PR |
| Q01717 | Trhr | Thyrotropin-releasing hormone receptor | Rattus norvegicus (Rat) | PR |
| P30936 | Sstr3 | Somatostatin receptor type 3 | Rattus norvegicus (Rat) | PR |
| Q9JHG3 | Aplnr | Apelin receptor | Rattus norvegicus (Rat) | PR |
| P43140 | Adra1a | Alpha-1A adrenergic receptor | Rattus norvegicus (Rat) | PR |
| P19327 | Htr1a | 5-hydroxytryptamine receptor 1A | Rattus norvegicus (Rat) | PR |
| P56719 | Hcrtr2 | Orexin receptor type 2 | Rattus norvegicus (Rat) | PR |
| P28564 | Htr1b | 5-hydroxytryptamine receptor 1B | Rattus norvegicus (Rat) | PR |
| P56718 | Hcrtr1 | Orexin/Hypocretin receptor type 1 | Rattus norvegicus (Rat) | PR |
| P28647 | Adora3 | Adenosine receptor A3 | Rattus norvegicus (Rat) | PR |
| P25102 | Hrh2 | Histamine H2 receptor | Rattus norvegicus (Rat) | PR |
| P23944 | Adra1d | Alpha-1D adrenergic receptor | Rattus norvegicus (Rat) | PR |
| Q8R415 | Prokr2 | Prokineticin receptor 2 | Rattus norvegicus (Rat) | PR |
| Q5QD24 | Taar3 | Trace amine-associated receptor 3 | Rattus norvegicus (Rat) | PR |
| P0C0W8 | Gpr139 | Probable G-protein coupled receptor 139 | Rattus norvegicus (Rat) | PR |
| P35370 | Oprl1 | Nociceptin receptor | Rattus norvegicus (Rat) | PR |
| P46090 | Cmklr2 | Chemerin-like receptor 2 | Rattus norvegicus (Rat) | PR |
| O08565 | Cxcr4 | C-X-C chemokine receptor type 4 | Rattus norvegicus (Rat) | PR |
| O97664 | CMKLR2 | Chemerin-like receptor 2 | Macaca mulatta (Rhesus macaque) | PR |
| O97666 | APLNR | Apelin receptor | Macaca mulatta (Rhesus macaque) | PR |
| Q56H79 | NPSR1 | Neuropeptide S receptor | Macaca mulatta (Rhesus macaque) | PR |
| Q18904 | npr-8 | Probable G-protein coupled receptor npr-8 | Caenorhabditis elegans | PR |
| Q09388 | gar-2 | Muscarinic acetylcholine receptor gar-2 | Caenorhabditis elegans | PR |
| B3DM66 | gpr161 | G-protein coupled receptor 161 | Xenopus tropicalis (Western clawed frog) (Silurana tropicalis) | PR |
| Q9W6A6 | opn1mw4 | Green-sensitive opsin-4 | Danio rerio (Zebrafish) (Brachydanio rerio) | PR |
| Q9W6A5 | opn1mw1 | Green-sensitive opsin-1 | Danio rerio (Zebrafish) (Brachydanio rerio) | PR |
| Q8AYM7 | opn1mw3 | Green-sensitive opsin-3 | Danio rerio (Zebrafish) (Brachydanio rerio) | PR |
| Q8AYN0 | opn1lw2 | Red-sensitive opsin-2 | Danio rerio (Zebrafish) (Brachydanio rerio) | PR |
| Q90X46 | gpr161 | G-protein coupled receptor 161 | Danio rerio (Zebrafish) (Brachydanio rerio) | PR |
| 10 | 20 | 30 | 40 | 50 | 60 |
| MEGISIYTSD | NYTEEMGSGD | YDSMKEPCFR | EENANFNKIF | LPTIYSIIFL | TGIVGNGLVI |
| 70 | 80 | 90 | 100 | 110 | 120 |
| LVMGYQKKLR | SMTDKYRLHL | SVADLLFVIT | LPFWAVDAVA | NWYFGNFLCK | AVHVIYTVNL |
| 130 | 140 | 150 | 160 | 170 | 180 |
| YSSVLILAFI | SLDRYLAIVH | ATNSQRPRKL | LAEKVVYVGV | WIPALLLTIP | DFIFANVSEA |
| 190 | 200 | 210 | 220 | 230 | 240 |
| DDRYICDRFY | PNDLWVVVFQ | FQHIMVGLIL | PGIVILSCYC | IIISKLSHSK | GHQKRKALKT |
| 250 | 260 | 270 | 280 | 290 | 300 |
| TVILILAFFA | CWLPYYIGIS | IDSFILLEII | KQGCEFENTV | HKWISITEAL | AFFHCCLNPI |
| 310 | 320 | 330 | 340 | 350 | |
| LYAFLGAKFK | TSAQHALTSV | SRGSSLKILS | KGKRGGHSSV | STESESSSFH | SS |